anti-muc-1/anti-cd40 bispecific antibody m0324
Generic: Anti-MUC-1/Anti-CD40 Bispecific Antibody M0324
anti-muc-1/anti-cd40 bispecific antibody m0324: 1 clinical trial tracked.
anti-muc-1/anti-cd40 bispecific antibody m0324 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about anti-muc-1/anti-cd40 bispecific antibody m0324, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (1)
An Open Label, Multicenter, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of M0324, a Bispecific (MUC-1 x CD40) Antibody as Monotherapy, in Combination With Pembrolizumab, and in Combination With Chemotherapy, in Participants With Selected Advanced Solid Tumors
Primary endpoint: Parts 1 and 2: Number of Participants With Dose Limiting Toxicities (DLTs)
Interventionalopen77 targetStarted 2025-10Completion 2029-025 sites · Canada, Japan, United StatesEMD Serono Research & Development Institute, Inc.